Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force
出版年份 2022 全文链接
标题
Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force
作者
关键词
cost-benefit analysis, economic evaluation, guidelines, methods, microeconomic analysis, reporting, standards
出版物
VALUE IN HEALTH
Volume 25, Issue 1, Pages 10-31
出版商
Elsevier BV
发表日期
2022-01-11
DOI
10.1016/j.jval.2021.10.008
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Differences in the Selection of Health State Utility Values by Sponsorship in Published Cost-Effectiveness Analyses
- (2021) Nathaniel Hendrix et al. MEDICAL DECISION MAKING
- Cost-Effectiveness of Quadrivalent Versus Trivalent Influenza Vaccination in the Dutch National Influenza Prevention Program
- (2021) Florian Zeevat et al. VALUE IN HEALTH
- Economic evaluation of nurse-led stroke aftercare addressing long-term psychosocial outcome: a comparison to care-as-usual
- (2021) Daan P J Verberne et al. BMJ Open
- Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States
- (2021) Richard Z. Xie et al. PHARMACOECONOMICS
- PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews
- (2021) Matthew J Page et al. BMJ-British Medical Journal
- Costs and cost-effectiveness of a comprehensive tuberculosis case finding strategy in Zambia
- (2021) Youngji Jo et al. PLoS One
- Reproducible research practices, openness and transparency in health economic evaluations: study protocol for a cross-sectional comparative analysis
- (2020) Ferrán Catalá-López et al. BMJ Open
- Economic evaluation of the OSAC randomised controlled trial: oral corticosteroids for non-asthmatic adults with acute lower respiratory tract infection in primary care
- (2020) Aida Moure-Fernandez et al. BMJ Open
- Cost‐effectiveness of a specialist smoking cessation package compared with standard smoking cessation services for people with severe mental illness in England: a trial‐based economic evaluation from the SCIMITAR+ study
- (2020) Jinshuo Li et al. ADDICTION
- Growth and capacity for cost‐effectiveness analysis in Africa
- (2020) Ari D. Panzer et al. HEALTH ECONOMICS
- Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis
- (2020) Jesse Elliott et al. PHARMACOECONOMICS
- Criteria and Process for Initiating and Developing an ISPOR Good Practices Task Force Report
- (2020) Daniel C. Malone et al. VALUE IN HEALTH
- Principles for deliberative processes in health technology assessment
- (2020) Kenneth Bond et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Reporting guidelines of health research studies are frequently used inappropriately
- (2020) Lisa Caulley et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Impact of Socioeconomic Differences on Distributional Cost-effectiveness Analysis
- (2020) Fan Yang et al. MEDICAL DECISION MAKING
- Perspective and Costing in Cost-Effectiveness Analysis, 1974–2018
- (2020) David D. Kim et al. PHARMACOECONOMICS
- Evaluation of the Cost-effectiveness of Infection Control Strategies to Reduce Hospital-Onset Clostridioides difficile Infection
- (2020) Anna K. Barker et al. JAMA Network Open
- Clinical Impact, Costs, and Cost-Effectiveness of Expanded SARS-CoV-2 Testing in Massachusetts
- (2020) Anne M Neilan et al. CLINICAL INFECTIOUS DISEASES
- Improving transparency to build trust in real-world secondary data studies for hypothesis testing-Why, what, and how: recommendations and a road map from the real-world evidence transparency initiative
- (2020) Lucinda S. Orsini et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- Preferred reporting items for systematic review and meta-analysis of diagnostic test accuracy studies (PRISMA-DTA): explanation, elaboration, and checklist
- (2020) Jean-Paul Salameh et al. BMJ-British Medical Journal
- Cost-effectiveness of post-treatment follow-up examinations and secondary prevention of tuberculosis in a high-incidence setting: a model-based analysis
- (2020) Florian M Marx et al. Lancet Global Health
- Distributional Cost-Effectiveness Analysis Comes of Age
- (2020) Richard Cookson et al. VALUE IN HEALTH
- Content of Health Economics Analysis Plans (HEAPs) for Trial-Based Economic Evaluations: Expert Delphi Consensus Survey
- (2020) Joanna C. Thorn et al. VALUE IN HEALTH
- Identification, Review, and Use of Health State Utilities in Cost-Effectiveness Models: An ISPOR Good Practices for Outcomes Research Task Force Report
- (2019) John Brazier et al. VALUE IN HEALTH
- SQUIRE-EDU (Standards for QUality Improvement Reporting Excellence in Education)
- (2019) Greg Ogrinc et al. ACADEMIC MEDICINE
- Assessing the cost-effectiveness of HPV vaccination strategies for adolescent girls and boys in the UK
- (2019) Samik Datta et al. BMC INFECTIOUS DISEASES
- Cost-Effectiveness of Alternative Uses of Polyvalent Meningococcal Vaccines in Niger: An Agent-Based Transmission Modeling Study
- (2019) S. M. Niaz Arifin et al. MEDICAL DECISION MAKING
- Adherence to the iDSI reference case among published cost-per-DALY averted studies
- (2019) Joanna Emerson et al. PLoS One
- Developing Open-Source Models for the US Health System: Practical Experiences and Challenges to Date with the Open-Source Value Project
- (2019) Jeroen P. Jansen et al. PHARMACOECONOMICS
- Equity-efficiency trade-offs associated with alternative approaches to deceased donor kidney allocation
- (2019) Bernadette Li et al. TRANSPLANTATION
- A Cost Analysis and Cost-Utility Analysis of a Community Pharmacist–Led Intervention on Reducing Cardiovascular Risk: The Alberta Vascular Risk Reduction Community Pharmacy Project (RxEACH)
- (2019) Helen Tam-Tham et al. VALUE IN HEALTH
- Value in Hepatitis C Virus Treatment: A Patient-Centered Cost-Effectiveness Analysis
- (2019) T. Joseph Mattingly et al. PHARMACOECONOMICS
- Doxycycline compared with prednisolone therapy for patients with bullous pemphigoid: cost-effectiveness analysis of the BLISTER trial
- (2018) J.M. Mason et al. BRITISH JOURNAL OF DERMATOLOGY
- The Future of Precision Medicine: Potential Impacts for Health Technology Assessment
- (2018) James Love-Koh et al. PHARMACOECONOMICS
- Cost-benefit analysis of vaccination: a comparative analysis of eight approaches for valuing changes to mortality and morbidity risks
- (2018) Minah Park et al. BMC Medicine
- Cost Effectiveness of a Comprehensive Approach for Hypertension Control in Low-Income Settings in Argentina: Trial-Based Analysis of the Hypertension Control Program in Argentina
- (2018) Federico Augustovski et al. VALUE IN HEALTH
- Reviewing progress in public involvement in NIHR research: developing and implementing a new vision for the future
- (2018) Sophie Staniszewska et al. BMJ Open
- Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report
- (2018) Josephine Mauskopf et al. VALUE IN HEALTH
- A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial
- (2017) Joanne R Chalmers et al. HEALTH TECHNOLOGY ASSESSMENT
- CONTRIBUTION OF STAKEHOLDER ENGAGEMENT TO THE IMPACT OF A HEALTH TECHNOLOGY ASSESSMENT: AN IRISH CASE STUDY
- (2017) Máirín Ryan et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Current UK Practices on Health Economics Analysis Plans (HEAPs): Are We Using Heaps of Them?
- (2017) Melina Dritsaki et al. PHARMACOECONOMICS
- Constrained Optimization Methods in Health Services Research—An Introduction: Report 1 of the ISPOR Optimization Methods Emerging Good Practices Task Force
- (2017) William Crown et al. VALUE IN HEALTH
- Cost-effectiveness research in cancer therapy: a systematic review of literature trends, methods and the influence of funding
- (2017) Daoud Al-Badriyeh et al. BMJ Open
- The influence of time horizon on results of cost-effectiveness analyses
- (2017) David D. Kim et al. Expert Review of Pharmacoeconomics & Outcomes Research
- Recommendations for the Conduct and Reporting of Modeling and Simulation Studies in Health Technology Assessment
- (2016) Issa J. Dahabreh et al. ANNALS OF INTERNAL MEDICINE
- Economic Evaluation in Global Perspective: A Bibliometric Analysis of the Recent Literature
- (2016) Catherine Pitt et al. HEALTH ECONOMICS
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses
- (2016) Gillian D. Sanders et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A history of the evolution of guidelines for reporting medical research: the long road to the EQUATOR Network
- (2016) Douglas G Altman et al. JOURNAL OF THE ROYAL SOCIETY OF MEDICINE
- Benefits, Challenges and Potential Strategies of Open Source Health Economic Models
- (2016) William C. N. Dunlop et al. PHARMACOECONOMICS
- Health Economics Analysis Plans: Where Are We Now ?
- (2016) JC Thorn et al. VALUE IN HEALTH
- The International Decision Support Initiative Reference Case for Economic Evaluation: An Aid to Thought
- (2016) Thomas Wilkinson et al. VALUE IN HEALTH
- Statistical Methods for the Analysis of Discrete Choice Experiments: A Report of the ISPOR Conjoint Analysis Good Research Practices Task Force
- (2016) A. Brett Hauber et al. VALUE IN HEALTH
- The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations
- (2015) Brian Hutton et al. ANNALS OF INTERNAL MEDICINE
- Preferred Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data
- (2015) Lesley A. Stewart et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- A Checklist for Reporting Valuation Studies of Multi-Attribute Utility-Based Instruments (CREATE)
- (2015) Feng Xie et al. PHARMACOECONOMICS
- Adapting the CHEERS Statement for Reporting Cost-Benefit Analysis
- (2015) Sabina Sanghera et al. PHARMACOECONOMICS
- AdViSHE: A Validation-Assessment Tool of Health-Economic Models for Decision Makers and Model Users
- (2015) P. Vemer et al. PHARMACOECONOMICS
- Dealing with Time in Health Economic Evaluation: Methodological Issues and Recommendations for Practice
- (2015) James F. O’Mahony et al. PHARMACOECONOMICS
- The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration
- (2015) Stavros Petrou et al. PHARMACOECONOMICS
- Criteria for Reporting the Development and Evaluation of Complex Interventions in healthcare: revised guideline (CReDECI 2)
- (2015) Ralph Möhler et al. Trials
- The Changing Face of the Cost-Utility Literature, 1990–2012
- (2015) Peter J. Neumann et al. VALUE IN HEALTH
- Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report
- (2015) Scott D. Ramsey et al. VALUE IN HEALTH
- STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies
- (2015) Patrick M Bossuyt et al. BMJ-British Medical Journal
- The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement
- (2015) Eric I. Benchimol et al. PLOS MEDICINE
- STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies
- (2015) Patrick M Bossuyt et al. BMJ-British Medical Journal
- The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling
- (2015) George A. K. van Voorn et al. Applied Health Economics and Health Policy
- Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide
- (2014) T. C. Hoffmann et al. BMJ-British Medical Journal
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
- (2013) D Husereau et al. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
- (2013) Don Husereau et al. BMC Medicine
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
- (2013) Don Husereau et al. CLINICAL THERAPEUTICS
- CONSOLIDATED HEALTH ECONOMIC EVALUATION REPORTING STANDARDS (CHEERS) STATEMENT
- (2013) Don Husereau et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
- (2013) Don Husereau et al. PHARMACOECONOMICS
- When Are Statins Cost-Effective in Cardiovascular Prevention? A Systematic Review of Sponsorship Bias and Conclusions in Economic Evaluations of Statins
- (2013) Ferrán Catalá-López et al. PLoS One
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement
- (2013) Don Husereau et al. VALUE IN HEALTH
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force
- (2013) Don Husereau et al. VALUE IN HEALTH
- Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force
- (2013) Sean D. Sullivan et al. VALUE IN HEALTH
- Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
- (2013) D. Husereau et al. BMJ-British Medical Journal
- An assessment of the construct validity of the ASCOT measure of social care-related quality of life with older people
- (2012) Juliette N Malley et al. Health and Quality of Life Outcomes
- Mapping the impact of patient and public involvement on health and social care research: a systematic review
- (2012) Jo Brett et al. HEALTH EXPECTATIONS
- Financial Relationships in Economic Analyses of Targeted Therapies in Oncology
- (2012) Antonis Valachis et al. JOURNAL OF CLINICAL ONCOLOGY
- Model Transparency and Validation
- (2012) David M. Eddy et al. MEDICAL DECISION MAKING
- Model Parameter Estimation and Uncertainty: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-6
- (2012) Andrew H. Briggs et al. VALUE IN HEALTH
- Inquiry into the Relationship between Equity Weights and the Value of the QALY
- (2012) Ana Bobinac et al. VALUE IN HEALTH
- Modeling Good Research Practices—Overview: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1
- (2012) J. Jaime Caro et al. VALUE IN HEALTH
- Model Transparency and Validation: A Report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7
- (2012) David M. Eddy et al. VALUE IN HEALTH
- Industry involvement and baseline assumptions of cost-effectiveness analyses: diagnostic accuracy of the Papanicolaou test
- (2011) N. P. Polyzos et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2
- (2011) David C. Hoaglin et al. VALUE IN HEALTH
- Conjoint Analysis Applications in Health—a Checklist: A Report of the ISPOR Good Research Practices for Conjoint Analysis Task Force
- (2011) John F.P. Bridges et al. VALUE IN HEALTH
- Conflict of interest in economic analyses of aromatase inhibitors in breast cancer: a systematic review
- (2010) Sekwon Jang et al. BREAST CANCER RESEARCH AND TREATMENT
- Modeling in pharmacoeconomic studies: Funding sources and outcomes
- (2010) Livio Garattini et al. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Classification of evidence in decision-analytic models of cost-effectiveness: A content analysis of published reports
- (2010) Suzy Paisley INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE
- Guidelines for conducting and reporting economic evaluation of fall prevention strategies
- (2010) J. C. Davis et al. OSTEOPOROSIS INTERNATIONAL
- Guidance for Developers of Health Research Reporting Guidelines
- (2010) David Moher et al. PLOS MEDICINE
- Uniform format for disclosure of competing interests in ICMJE journals
- (2009) J. M. Drazen et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Modelling Methods for Pharmacoeconomics and Health Technology Assessment
- (2009) James E Stahl PHARMACOECONOMICS
- Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines
- (2009) Natasha K. Stout et al. PHARMACOECONOMICS
- Dealing with heterogeneity of treatment effects: is the literature up to the challenge?
- (2009) Nicole B Gabler et al. Trials
- Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report
- (2009) Michael Drummond et al. VALUE IN HEALTH
- Good Research Practices for Measuring Drug Costs in Cost Effectiveness Analyses: Issues and Recommendations: The ISPOR Drug Cost Task Force Report—Part I
- (2009) Joel W. Hay et al. VALUE IN HEALTH
- Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applications
- (2008) Mireille M Goetghebeur et al. BMC HEALTH SERVICES RESEARCH
- Subgroups and Heterogeneity in Cost-Effectiveness Analysis
- (2008) Mark Sculpher PHARMACOECONOMICS
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started